Molecular Profiling of Endometrial Cancer From TCGA to Clinical Practice
Molecular classification provides an objective, reproducible framework for categorization of endometrial cancers (ECs), informing prognosis and selection of therapy. Currently, the uptake of molecular classification, integration in to EC management algorithms, and enrollment in molecular subtype-specific clinical trials lags behind what it could be. Access to molecular testing is not uniform, and subsequent management (surgical, adjuvant therapy) is unacceptably variable. We are in the midst of a critical landscape change in this disease site, with increasing emphasis on the integration of molecular features in EC care that can potentially improve standard of care globally. This article summarizes the rationale for molecular classification of ECs, strategies for implementation in low and high resource settings, and actionable opportunities based on this information.
Submitted August 15, 2022; final revision received October 6, 2022; accepted for publication November 7, 2022.
Disclosures: Dr. McAlpine has disclosed receiving an education grant from GlaxoSmithKline. Dr. Jamieson has disclosed no relevant financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
© 2019-2023 National Comprehensive Cancer Network